ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

Researchers at Fondazione Policlinico Universitario Agostino Gemelli IRCCS have developed a promising machine learning algorithm capable of predicting survival and cause of death for patients with ...

The FDA has acknowledged receipt of the supplemental Biologics License Application (sBLA) for nogapendekin alfa inbakicept-pmln (Anktiva) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

Theralase Technologies (TSXV:TLT) has shown in pre-clinical trials that its flagship Rutherrin, when activated by X-Ray, is ...

LEGEND pivotal cohort update planned for a spring 2026 medical conference12-month complete response data from LEGEND pivotal cohort expected in 2H 2026Biologics License Application (BLA) submission ...

The post If Your Period Is Quietly Running Your Life, It’s Time to Pay Attention appeared first on Katie Couric Media.

Following multiple meetings with the FDA, ImmunityBio submitted additional information requested by the Agency to support its supplemental BLA (sBLA) for papillary ...

Investigators sought to determine if the gemcitabine intravesical system plus intravenous cetrelimab could improve survival for patients with muscle-invasive bladder cancer who did not receive radical ...

Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) climbed 25% on Monday after the company released 12-month interim results ...

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time ...